| Next 10 |
Ad
SKYE News and Press Skye Bioscience Inc Com
News | Skye Bioscience Inc Com (NASDAQ:SKYE)
- SKYE - A Weight Loss Drug Candidate Essentially For Free As Skye Bioscience Is Trading At Cash Value
2025-04-16 07:50:14 ET Summary Weight loss drug stocks like Novo Nordisk have dropped significantly lately. This presents potential value opportunities in a market projected to grow to $105 billion by 2035. Skye Bioscience's nimacimab, in Phase 2a trials, shows promise with signif...
-
2025-04-15 10:34:57 ET DENVER, Colo., Apr 15, 2025 ( 247marketnews.com ) -Today’s top news and trades include weight loss and super fibers. MetaVia (NASDAQ:MTVA) unveiled Phase 1 MAD trial results for DA-1726, its novel 3:1 ratio GLP-1/glucagon dual receptor agonist aimed at ...
-
2025-03-20 21:59:22 ET More on Skye Bioscience Skye Bioscience, Inc. (SKYE) Q4 2024 Earnings Call Transcript Skye Bioscience GAAP EPS of -$0.24 beats by $0.04 Smaller biotechs see new mechanisms of action as future of obesity treatments Seeking Alpha’s...
-
2025-03-20 21:58:54 ET Skye Bioscience, Inc. (SKYE) Q4 2024 Earnings Conference Call March 20, 2025 04:30 PM ET Company Participants Bernie Hertel - Head of Investor Relations Punit Dhillon - President and Chief Executive Officer Kaitlyn Arsenault - Chief Financi...
-
2025-03-20 16:06:28 ET More on Skye Bioscience Smaller biotechs see new mechanisms of action as future of obesity treatments Seeking Alpha’s Quant Rating on Skye Bioscience Historical earnings data for Skye Bioscience Financial information for Skye Bio...
-
2025-03-20 10:00:00 ET Major earnings expected after the bell on Thursday include: Micron Technology ( MU ) NIKE ( NKE ) FedEx Corporation ( FDX ) Luminar Technologies ( LAZR ) Ouster ( OUST ) Read the full article on Seeking Alpha For...
-
Papaya Growth Opportunity Corp. I (PPYA) is expected to report for quarter end 2024-12-31 KinderCare Learning Companies Inc. (KLC) is expected to report $0.04 for Q4 2024 Recordati SpA (RCDTF) is expected to report for quarter end 2024-12-31 InflaRx N.V. (IFRX) is expected to report $...
-
2025-03-19 17:35:13 ET More on Skye Bioscience Smaller biotechs see new mechanisms of action as future of obesity treatments Seeking Alpha’s Quant Rating on Skye Bioscience Historical earnings data for Skye Bioscience Financial information for Skye Bio...
-
SAN DIEGO, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biopharmaceutical company focused on unlocking new therapeutic pathways for obesity and other metabolic health disorders, is pleased to announce the participation of Punit Dh...
-
2025-02-10 12:34:35 ET More on Scholar Rock, Skye Bioscience Scholar Rock: More Than Just An SMA Biotech With Q2 2025 Obesity Treatment Data Scholar Rock: Good Company, But This Ship Has Sailed Scholar Rock: Likely Approval In SMA Plus Obesity Data In 2025 Intrigue, ...
Stock Information
Get SKYE Alerts
News, Short Squeeze, Breakout and More Instantly...
Skye Bioscience Inc Com Company Name:
SKYE Stock Symbol:
NASDAQ Market:
-1.68% G/L:
$1.82 Last:
415,401 Volume:
$1.82 Open:
$1.82 Close:
Skye Bioscience Inc Com Website:
Ad
-
2025-04-15 10:34:57 ET DENVER, Colo., Apr 15, 2025 ( 247marketnews.com ) -Today’s top news and trades include weight loss and super fibers. MetaVia (NASDAQ:MTVA) unveiled Phase 1 MAD trial results for DA-1726, its novel 3:1 ratio GLP-1/glucagon dual receptor agonist aimed at ...
-
Papaya Growth Opportunity Corp. I (PPYA) is expected to report for quarter end 2024-12-31 KinderCare Learning Companies Inc. (KLC) is expected to report $0.04 for Q4 2024 Recordati SpA (RCDTF) is expected to report for quarter end 2024-12-31 InflaRx N.V. (IFRX) is expected to report $...
-
SAN DIEGO, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biopharmaceutical company focused on unlocking new therapeutic pathways for obesity and other metabolic health disorders, is pleased to announce the participation of Punit Dh...